CHRISTOPHER RUMPLIK: Open Payments
NPI 1144847286 · AGAWAM, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,172 in 238 payments from 23 companies in 2025. Trend: 2023 $3,509 · 2024 $5,874 · 2025 $5,172
Food & beverage: $4,895Education: $278
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 44 | $699 |
| Janssen Biotech, Inc. | 15 | $519 |
| E.R. Squibb & Sons, L.L.C. | 19 | $489 |
| UCB, Inc. | 30 | $463 |
| Arcutis Biotherapeutics, Inc. | 17 | $364 |
| Novartis Pharmaceuticals Corporation | 19 | $359 |
| Galderma Laboratories, L.P. | 17 | $326 |
| GENZYME CORPORATION | 8 | $303 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 10 | $245 |
| Lilly USA, LLC | 11 | $210 |
Products named: TREMFYA, Sotyktu, Bimzelx, DUPIXENT, SKYRIZI, Zoryve, COSENTYX, RINVOQ.
Industry payments across MA — which companies pay providers there.
